{"id":1036,"date":"2021-05-27T08:35:11","date_gmt":"2021-05-27T08:35:11","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=1036"},"modified":"2021-05-27T08:35:11","modified_gmt":"2021-05-27T08:35:11","slug":"11-may-2021-thymosin-alpha1a-significantly-shorter-sars-cov-2-rna-shedding-duration-13-vs-16-days-p-0-025","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/11-may-2021-thymosin-alpha1a-significantly-shorter-sars-cov-2-rna-shedding-duration-13-vs-16-days-p-0-025\/","title":{"rendered":"(11 May 2021) Thymosin alpha1a- significantly shorter SARS-CoV-2 RNA shedding duration (13 vs. 16 days, p = 0.025)"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching<\/p>\n<p>https:\/\/doi.org\/10.3389\/fmed.2021.664776<\/p>\n<p class=\"\">Among 1,388 enrolled patients, 232 patients (16.7%) received both Thymosin-alpha1 therapy and standard therapy (Thymosin-alpha1 group), and 1,156 patients (83.3%) received standard therapy (control group). The proportion of patients that progressed to severe COVID-19 is 2.17% for the Thymosin-alpha1 group and 2.71% for the control group (p = 0.736). The COVID-19-related mortality is 0.54% for the Thymosin-alpha1 group and 0 for the control group (p = 0.317). Compared with the control group, the Thymosin-alpha1 group had significantly shorter SARS-CoV-2 RNA shedding duration (13 vs. 16 days, p = 0.025) and hospital stay (14 vs. 18 days, p &lt; 0.001). No statistically significant difference was found between the Thymosin-alpha1 group and control group in duration of symptoms (median, 4 vs. 3 days, p = 0.843) and antibiotic utilization rate (14.1% vs. 15.2%, p = 0.768). For non-severe patients with COVID-19, Thymosin-alpha1 can shorten viral RNA shedding duration and hospital stay but did not prevent COVID-19 progression and reduce COVID-19-related mortality rate.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching https:\/\/doi.org\/10.3389\/fmed.2021.664776 Among 1,388 enrolled patients, 232 patients (16.7%) received both Thymosin-alpha1 therapy and standard therapy (Thymosin-alpha1 group), and 1,156 patients&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/11-may-2021-thymosin-alpha1a-significantly-shorter-sars-cov-2-rna-shedding-duration-13-vs-16-days-p-0-025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(11 May 2021) Thymosin alpha1a- significantly shorter SARS-CoV-2 RNA shedding duration (13 vs. 16 days, p = 0.025)&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,130],"tags":[131],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1036"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=1036"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1036\/revisions"}],"predecessor-version":[{"id":1037,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1036\/revisions\/1037"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=1036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=1036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=1036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}